New immunotherapy cocktails aim to tackle Hard-to-Treat breast cancer

NCT ID NCT03280563

Completed Disease control Sponsor: Hoffmann-La Roche Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested several immunotherapy-based drug combinations in 144 people with advanced hormone receptor-positive, HER2-negative breast cancer that had worsened after initial treatment. Participants received atezolizumab (Tecentriq) along with other drugs like bevacizumab or fulvestrant. The goal was to see if these combinations could shrink tumors or slow disease progression. The trial is now complete, and results will help guide future treatment options.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

Atezolizumab (Tecentriq) plus other drugs like bevacizumab or fulvestrant

What this could lead to

If successful, this could provide new treatment options for people with advanced breast cancer that has stopped responding to standard therapies.

What could go wrong

This is an early-phase study with a small number of participants, so results may not apply to everyone. Immunotherapy can cause immune-related side effects.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast neoplasm hormone receptor-positive breast cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BREAST NEOPLASMS

Contacts and locations

Show contact details

Locations

Johns Hopkins Sidney Kimmel Comprehensive Cancer Center

Baltimore, Maryland, 21231, United States
Levine Cancer Institute

Charlotte, North Carolina, 28204, United States
Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center

Torrance, California, 90502, United States
Memorial Sloan Kettering Cancer Center

New York, New York, 10065, United States
National Cancer Center

Gyeonggi-do, 10408, South Korea
Northwest Georgia Oncology Centers PC - Marietta

Marietta, Georgia, 30060, United States
Providence Cancer Center

Portland, Oregon, 97231, United States
Rabin Medical Center-Beilinson Campus

Petah Tikva, 4941492, Israel
Rambam Medical Center

Haifa, 3109601, Israel
Sarah Cannon Research Institute / Tennessee Oncology

Nashville, Tennessee, 37203, United States
Seoul National University Hospital

Seoul, 03080, South Korea
Shaare Zedek Medical Center

Jerusalem, 9103102, Israel
Sheba Medical Center

Ramat Gan, 5262100, Israel
Stanford Cancer Institute

Stanford, California, 94305-5456, United States
Tel Aviv Sourasky Medical Center

Tel Aviv, 64239, Israel
Thomas Jefferson University Hospital

Philadelphia, Pennsylvania, 19107, United States
UCSF Helen Diller Family CCC

San Francisco, California, 94158, United States
UPMC Pinnacle Health System

Harrisburg, Pennsylvania, 17102, United States
Univ of Pittsburgh Sch of Med

Pittsburgh, Pennsylvania, 15213, United States
University of Alabama at Birmingham

Birmingham, Alabama, 35249, United States
University of Ulsan College of Medicine - Asan Medical Center

Seoul, 05505, South Korea
Wellness Oncology and Hematology - Main Office

West Hills, California, 91307, United States